Source: Cancer Chemotherapy and Pharmacology. Unidade: FMRP
Subjects: ENTEROPATIAS, ANTINEOPLÁSICOS, CITOCINAS, RECEPTORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Ronaldo A. et al. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemotherapy and Pharmacology, v. 78, n. 5, p. 881-893, 2016Tradução . . Disponível em: https://doi.org/10.1007/s00280-016-3139-y. Acesso em: 06 nov. 2024.APA
Ribeiro, R. A., Wanderley, C. W. S., Wong, D. V. T., Mota, J. M. S. C., Leite, C. A. V. G., Souza, M. H. L. P., et al. (2016). Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemotherapy and Pharmacology, 78( 5), 881-893. doi:10.1007/s00280-016-3139-yNLM
Ribeiro RA, Wanderley CWS, Wong DVT, Mota JMSC, Leite CAVG, Souza MHLP, Cunha F de Q, Lima Junior RCP. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives [Internet]. Cancer Chemotherapy and Pharmacology. 2016 ; 78( 5): 881-893.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1007/s00280-016-3139-yVancouver
Ribeiro RA, Wanderley CWS, Wong DVT, Mota JMSC, Leite CAVG, Souza MHLP, Cunha F de Q, Lima Junior RCP. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives [Internet]. Cancer Chemotherapy and Pharmacology. 2016 ; 78( 5): 881-893.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1007/s00280-016-3139-y
